vs
CLOVER HEALTH INVESTMENTS, CORP.（CLOV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CLOVER HEALTH INVESTMENTS, CORP.的1.6倍（$772.1M vs $487.7M），Revvity净利率更高（12.7% vs -10.1%，领先22.9%），CLOVER HEALTH INVESTMENTS, CORP.同比增速更快（44.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-69.0M），过去两年CLOVER HEALTH INVESTMENTS, CORP.的营收复合增速更高（18.6% vs 9.0%）
克利弗健康投资公司是2014年成立的美国医疗保健企业，主营联邦医疗保险优势计划保险产品，是与美国政府直接签约合作的机构。目前公司为美国11个州的联邦医疗保险参保人提供健康管理服务，并已于2021年1月8日公开上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CLOV vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$487.7M
营收增速更快
CLOV
高出38.9%
5.9%
净利率更高
RVTY
高出22.9%
-10.1%
自由现金流更多
RVTY
多$230.8M
$-69.0M
两年增速更快
CLOV
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $487.7M | $772.1M |
| 净利润 | $-49.3M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -10.1% | 14.5% |
| 净利率 | -10.1% | 12.7% |
| 营收同比 | 44.7% | 5.9% |
| 净利润同比 | -123.2% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLOVRVTY
| Q4 25 | $487.7M | $772.1M | ||
| Q3 25 | $496.6M | $698.9M | ||
| Q2 25 | $477.6M | $720.3M | ||
| Q1 25 | $462.3M | $664.8M | ||
| Q4 24 | $337.0M | $729.4M | ||
| Q3 24 | $331.0M | $684.0M | ||
| Q2 24 | $356.3M | $691.7M | ||
| Q1 24 | $346.9M | $649.9M |
净利润CLOVRVTY
| Q4 25 | $-49.3M | $98.4M | ||
| Q3 25 | $-24.4M | $46.7M | ||
| Q2 25 | $-10.6M | $53.9M | ||
| Q1 25 | $-1.3M | $42.2M | ||
| Q4 24 | $-22.1M | $94.6M | ||
| Q3 24 | $-9.2M | $94.4M | ||
| Q2 24 | $7.4M | $55.4M | ||
| Q1 24 | $-19.2M | $26.0M |
毛利率CLOVRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.5% | 56.3% | ||
| Q2 24 | 30.3% | 55.7% | ||
| Q1 24 | 23.6% | 54.6% |
营业利润率CLOVRVTY
| Q4 25 | -10.1% | 14.5% | ||
| Q3 25 | -4.9% | 11.7% | ||
| Q2 25 | -2.2% | 12.6% | ||
| Q1 25 | -0.3% | 10.9% | ||
| Q4 24 | -6.4% | 16.3% | ||
| Q3 24 | -2.7% | 14.3% | ||
| Q2 24 | 2.0% | 12.4% | ||
| Q1 24 | -6.5% | 6.8% |
净利率CLOVRVTY
| Q4 25 | -10.1% | 12.7% | ||
| Q3 25 | -4.9% | 6.7% | ||
| Q2 25 | -2.2% | 7.5% | ||
| Q1 25 | -0.3% | 6.4% | ||
| Q4 24 | -6.6% | 13.0% | ||
| Q3 24 | -2.8% | 13.8% | ||
| Q2 24 | 2.1% | 8.0% | ||
| Q1 24 | -5.5% | 4.0% |
每股收益（稀释后）CLOVRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.3M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $308.7M | $7.3B |
| 总资产 | $541.0M | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLOVRVTY
| Q4 25 | $78.3M | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $194.5M | $1.2B | ||
| Q3 24 | $288.0M | $1.2B | ||
| Q2 24 | $254.8M | $2.0B | ||
| Q1 24 | $208.3M | $1.7B |
股东权益CLOVRVTY
| Q4 25 | $308.7M | $7.3B | ||
| Q3 25 | $340.9M | $7.4B | ||
| Q2 25 | $344.2M | $7.6B | ||
| Q1 25 | $336.1M | $7.6B | ||
| Q4 24 | $341.1M | $7.7B | ||
| Q3 24 | $342.2M | $7.9B | ||
| Q2 24 | $324.9M | $7.9B | ||
| Q1 24 | $292.5M | $7.8B |
总资产CLOVRVTY
| Q4 25 | $541.0M | $12.2B | ||
| Q3 25 | $559.7M | $12.1B | ||
| Q2 25 | $575.0M | $12.4B | ||
| Q1 25 | $583.7M | $12.4B | ||
| Q4 24 | $580.7M | $12.4B | ||
| Q3 24 | $653.0M | $12.8B | ||
| Q2 24 | $674.2M | $13.4B | ||
| Q1 24 | $671.8M | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-66.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-69.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -14.1% | 21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-69.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CLOVRVTY
| Q4 25 | $-66.9M | $182.0M | ||
| Q3 25 | $12.1M | $138.5M | ||
| Q2 25 | $5.4M | $134.3M | ||
| Q1 25 | $-16.3M | $128.2M | ||
| Q4 24 | $34.8M | $174.2M | ||
| Q3 24 | $50.0M | $147.9M | ||
| Q2 24 | $44.8M | $158.6M | ||
| Q1 24 | $25.9M | $147.6M |
自由现金流CLOVRVTY
| Q4 25 | $-69.0M | $161.8M | ||
| Q3 25 | $11.4M | $120.0M | ||
| Q2 25 | $4.8M | $115.5M | ||
| Q1 25 | $-16.5M | $112.2M | ||
| Q4 24 | $33.3M | $149.8M | ||
| Q3 24 | $49.6M | $125.6M | ||
| Q2 24 | $44.4M | $136.6M | ||
| Q1 24 | $25.5M | $129.7M |
自由现金流率CLOVRVTY
| Q4 25 | -14.1% | 21.0% | ||
| Q3 25 | 2.3% | 17.2% | ||
| Q2 25 | 1.0% | 16.0% | ||
| Q1 25 | -3.6% | 16.9% | ||
| Q4 24 | 9.9% | 20.5% | ||
| Q3 24 | 15.0% | 18.4% | ||
| Q2 24 | 12.5% | 19.7% | ||
| Q1 24 | 7.3% | 20.0% |
资本支出强度CLOVRVTY
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.1% | 3.3% | ||
| Q2 24 | 0.1% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率CLOVRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 6.04× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLOV
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
